PRME (Prime Medicine) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 02, 2026)


PRME Prime Medicine Inc PRME
28 GF Score
Price $3.87
! 5 Warning Signs
View Full Analysis

What is Prime Medicine 5-Year Yield-on-Cost %?

Prime Medicine PRME -0.39% 28 5-Year Yield-on-Cost % is 0.00 as of Jul. 02, 2026. GuruFocus rates PRME with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 153 Biotechnology companies, Prime Medicine ranks worse than 653594.12% on this metric.

Prime Medicine's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Prime Medicine's 5-Year Yield-on-Cost % or its related term are showing as below:



PRME's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.75
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Prime Medicine  (NAS:PRME) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Prime Medicine 5-Year Yield-on-Cost % Related Terms

PRME vs EIKN, CRMD, STTK: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Prime Medicine's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prime Medicine 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Prime Medicine's 5-Year Yield-on-Cost % falls into.


PRME
28GF Score
Prime Medicine Inc PRME
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prime Medicine 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Prime Medicine is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Prime Medicine (PRME) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Prime Medicine and its competitors. According to the industry distribution chart, Prime Medicine ranks #999999 out of 153 companies in the Biotechnology industry.
Is Prime Medicine's 5-Year Yield-on-Cost % too high?
Prime Medicine's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Prime Medicine ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prime Medicine has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's 5-Year Yield-on-Cost % compare to EIKN and CRMD?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Prime Medicine in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.75, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Prime Medicine and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Prime Medicine's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Prime Medicine (PRME), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
28GF Score

Get the complete analysis for PRME

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.87
Price